RxDoctor Payments Data

Jessica Derochie

Family · Norwich, NYNPI 1215547245

Payments from drug & device makers

$14,913in general payments, 2019–2025

Across 851 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$14,913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,913 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$6,407
Medicare patients
63
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$114,106
OzempicSemaglutide73$82,988
FarxigaDapagliflozin Propanediol64$59,876
Breztri AerosphereBudesonide/Glycopyr/Formoterol68$50,180
EliquisApixaban49$47,547
RexultiBrexpiprazole27$43,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$41,898
RybelsusSemaglutide20$40,908
VraylarCariprazine Hcl16$33,914
XareltoRivaroxaban21$31,561
MounjaroTirzepatide30$29,350
VascepaIcosapent Ethyl39$28,302
TrulicityDulaglutide19$23,596
MyrbetriqMirabegron15$17,518
Tresiba Flextouch U-100Insulin Degludec24$12,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,678$123,89693 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,337$114,738153 claims
Boehringer IngelheimJardiance$1,636$114,10682 claims
Lilly USA, LLCMounjaro, Trulicity$1,094$52,94649 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,159$50,19974 claims
PfizerEliquis$300$47,54749 claims
Otsuka America Pharmaceutical, Inc.Rexulti$199$43,87627 claims
AbbVieVraylar$2,211$33,91416 claims
Johnson & JohnsonXarelto$463$31,56121 claims
Astellas Pharma US IncMyrbetriq$186$17,51815 claims
NovartisEntresto$33$10,99915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Norwich

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →